Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IVOB 1.00
IVOB .87
IVOB .74 news:
INVO Bioscience Receives FDA Clearance for INVOcell Fertility Treatment
Revolutionary device and procedure provides natural, safe, effective and economical fertility treatment option.
MEDFORD, Mass., Nov. 3, 2015 /PRNewswire/ -- INVO Bioscience, Inc. (OTC Pink: IVOB), a medical device company focused on treatment option for patients diagnosed with infertility, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company's de novo request for the INVOcell™. As a result, INVOcell is the first intravaginal culture system granted marketing clearance in the United States, providing millions of infertile couples across the country access to this revolutionary infertility treatment.
Katie Karloff, chief executive officer of INVO Bioscience, commented, "INVOcell has the ability to significantly transform the way in which fertility clinics across the United States assist infertile patients to achieve their desired outcomes in a simpler, more natural and cost effective manner. It has been a long process to de novo clearance and we are so pleased to have this approval from the FDA to begin marketing and selling in the United States. With this critical approval, we look forward to developing the partnerships necessary to bring this device to millions of patients across the United States."
In 2012, the World Health Organization (WHO) estimated there are more than 48.5 million couples worldwide that have fertility issues, of which 6.7 million of the couples are in the United States. Less than 10 percent of thee couples who need assistance receive it, making it a substantial untapped market.
The INVOcell is used for the incubation of eggs and sperm during fertilization of early embryo development. Unlike conventional infertility treatments such as in vitro fertilization (IVF), where the eggs and sperm develop into embryos in a laboratory, the INVOcell utilizes the women's vagina as a natural incubator to support embryo development. In clinical studies, the INVOcell procedure produced pregnancy rates equivalent to traditional IVF treatments.
The key features and benefits of the INVOcell device and procedure include:
Providing a more natural and stable vaginal incubation than in a conventional IVF incubator;
Providing psychological benefits to patients/couples and promoting greater involvement by couples;
Reducing the risk of incorrect embryo transfers; and
Reducing the cost of infertility treatments and increasing geographic accessibility.
INVOcell has gained national attention over the last year from the infertility community as a safe, effective, and low cost fertility treatment option. During the 2015 American Society of Reproduction Medicine (ASRM) conferences, Dr. Kevin Doody of Bedford, Texas presented results of a randomized 40 patient comparative study demonstrating the INVOcell procedure performed equivalent to that of IVF, with INVOcell producing a 65% pregnancy rate. This presentation also focused on the relative cost reductions that the INVOcell procedure can allow for compared to traditional IVF treatment. As a result of the safety, equivalence of pregnancy rates, and lower overall cost of procedure, ASRM endorsed INVOcell as a viable process for treating infertile patients.
Claude Ranoux, president and founder of INVO Bioscience, commented, " My goal was to create an alternative treatment to traditional IVF procedures that could produce the desired results in a simpler and more cost effective manner to allow treatment to many more infertile couples. I believe the INVOcell procedure has the ability to significantly transform the way in which infertile couples go about achieving pregnancy. It is my hope that years from now it becomes the gold standard of use throughout the United States and the world. Based on current patient acceptance I think we are on the right track."
Lori Kahler, managing director of The RC Insight Group who was instrumental in the company achieving this milestone stated, "I am thrilled to see this state-of-the-art technology available in the United States. For couples struggling with infertility, INVOcell is game changing and offers benefits that are unobtainable with traditional IVF. It is rare when a company's innovation is truly disruptive to an industry, yet INVO Bioscience's vision and dedication to the treatment of infertility did just that, and now couples have access to affordable and accessible treatment."
Another study by Dr. Elkin Lucena and his team at the Colombian Fertility and Sterility Center (CECOLFES) in Bogota showed that INVOcell vaginal embryo culture is effective for couples with male factor infertility who use intra-cytoplasmic sperm injection (ICSI).
Charles Coddington, MD, the 2014 President of ASRM, stated, "These studies show how innovative technology may be able to reduce some of the laboratory costs and lead to wider availability of treatment."
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Medford, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Kathleen Karloff, CEO
INVO Bioscience, Inc.
978-878-9505 ext. 504
www.invobioscience.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/invo-bioscience-receives-fda-clearance-for-invocell-fertility-treatment-300171401.html
SOURCE INVO Bioscience, Inc.
Moving now
.0015 x .002 Who are the dummies selling? Sheesh, learn how to trade.
PYCT .0001 news, huge o/s though:
PayChest Restructures More Than $1 Million of Debt
HONG KONG, CHINA--(Marketwired - November 03, 2015) - PayChest, Inc. (OTC PINK: PYCT)
PayChest is pleased to announce the Company has improved its balance sheet by converting $1,070,699 of current liabilities to Preferred B Shares. Negotiations with creditors enabled the transfer of these debts to Preferred B Shares with payments in lieu of interest totaling $113,000 also delivered in Preferred B Shares.
This follows the recent write-downs of certain assets as announced on September 22, 2015.
The restructuring enables the Company to focus proceeds of the $500,000 financing, as announced in July 2015, on funding commercial production and business development rather than being used for debt repayment or interest.
The Company completed this restructuring effective September 30, 2015 resulting in an outstanding balance of current liabilities of $73,243. This will be reflected in the Third Quarter Financial Report.
The result is a balance sheet with significantly less debt and better reflects the Company's focus on the Mibella® product range.
We expect to make an announcement shortly as to when commercial production of the Mibella® product will begin.
NOTE ABOUT FORWARD-LOOKING STATEMENTS
Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company's filings with OTC Markets http://www.otcmarkets.com/stock/PYCT/financials.
Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward looking statements because they involve unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward-looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, should and similar expressions and by the context in which they are used. Such statements are based upon current expectations of the Company and speak only as of the date made.
Historical news releases on the Company can be found at http://www.paychest.com/news.htm.
Contact:
PayChest, Inc.
ir@paychest.com
Tom Hands :
1-302-724-6944
Source: Marketwired (Nov 3, 2015 09:01:14 EST)
News by QuoteMedia
www.quotemedia.com
gm bounce team
gm lotto players
gn bounce team
gn lotto players
I see, nice buys.
VRCH .25 up, easy mover, low float-real assets
gm ARTIST
ACOL .002
ACOL .0177 news:
Letter to Shareholders: From the Desk of Curt Fairbrother CEO
CORONA, CA--(Marketwired - November 02, 2015) - Acology Inc. (OTC PINK: ACOL)
Dear Acology Shareholders:
Since my last letter to you on October 7 there have been several positive developments that I want to share with you.
One year ago, in October 2014, Acology had contracted and sold its products to less than 45 North American distributors. By the end of 2015 Acology will have acquired, contracted and sold products to more than 900 domestic and international distributors, wholesalers, merchants and brokers. This impressive achievement has succeeded in increasing sales for each calendar month of 2015. These results, along with the continuing execution of both new and ongoing marketing efforts, promise steady growth for calendar 2016. Reorders have continued to advance due to very aggressive sales and marketing and a strong social media campaign. October will set another record for the largest gross-sales receipts in the company's history.
Acology is advancing on the medical-device front as well. After welcoming Dr. Vincent Nguyen, DO.,CMD and Program Director of Hoag Hospital's CARES Palliative Care Program and colleges Josh Luke, PHD, Director of the National Re-Admission Coalition Cooperative and Michael Demoratz, PHD, Administrator of 24/7 Care to Acology's Advisory Board, we gathered in formal session on the 27th of October for the purpose of beginning the collaboration needed to make a strong entrance into the hospice, palliative and cognitive care industries with our signature product, The MedTainer™. Affording Acology executives their rare insight and expertise in these fields these three distinguished men have begun guiding Acology to contacts in the medical device and patient care industry, including large corporate entities centered in Southern California. The MedTainer is now in clinical trials with several large, nation-wide patient care providers who have been supplied with Acology's patented product and are using MedTainers to improve their patient's medication control. In the short time that the trials have run the feedback from clinicians and care givers has been very positive. Acology's intention is to fully capitalize these successful clinical outcomes and create substantial MedTainer sales in these markets.
Responding to the need to increase the capabilities and capacity of our business operations Acology's expansion and building of the new 5,000 sq.ft. extension continues and the intention is to be fully operational by the close of 2015.
Thank you for your continued support.
Sincerely,
Curt Fairbrother, CEO
Acology Inc. / D&C Distributors, LLC
Safe Harbor Statement
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
Acology Inc. and D&C Distributors are located in their production and distribution facility at 1620 Commerce St. Corona, California, 92880. Acology trades on the OTC under the call letters ACOL. The company's email is www.Acologyinc.com. Please send inquiries to info@acologyinc.com or call (844) ACOLOGY (844-226-5649).
Contact:
Acology Inc.
info@acologyinc.com
Source: Marketwired (Canada) (Nov 2, 2015 03:00:12 EST)
News by QuoteMedia
www.quotemedia.com
gm bounce team
gm gum & lotto players
Flowers year 'round. Just plant and occasionally water.
https://www.facebook.com/viscontipsl/photos/a.315460031984784.1073741828.314119148785539/445369652327154/?type=3&theater
Have a good w/e bounce team
enjoy the w/e lotto players
u2 mk, gn
UOIP .006 X .0092 looks like a reverse merger:
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10979018
Good stuff!